Evidence map›Paper›PMID 27025484›Full record

ArticleDoklady. Biochemistry and biophysics2016

Highly immunogenic variant of attenuated vaccinia virus.

S N Yakubitskyi, I V Kolosova, R A Maksyutov, S N Shchelkunov

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05762523 (An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05762523 phase1completednot on this mapstarted 2019, after this paper: background citation

An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC∆6 Vaccine) Based on Vaccinia Virus, in Volunteers Aged 18-40 Years

TypeinterventionalSponsorFederal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"Ran2019 to 2020Enrolled60ConditionsSmallpox, Monkeypox, Cowpox, Vaccinia Virus InfectionArmsVAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU, Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S N YakubitskyiVector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia. snshchel@vector.nsc.ru.
I V KolosovaVector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia.
R A MaksyutovVector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia.
S N ShchelkunovVector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia.
State Research Center of Virology and Biotechnology VECTOR · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The LIVPΔ6 strain of vaccinia virus (VACV) was created by genetic engineering on the basis of previously obtained attenuated 1421ABJCN strain by target deletion of the A35R gene encoding an inhibitor of antigen presentation by the major histocompatibility complex class II. 1421ABJCN is the LIVP strain of VACV with five inactivated virulence genes encoding hemagglutinin (A56R), γ-interferon-binding protein (B8R), thymidine kinase (J2R), complement-binding protein (C3L), and Bcl2-like inhibitor of apoptosis (N1L). The highly immunogenic LIVPΔ6 strain could be an efficient fourth-generation attenuated vaccine against smallpox and other orthopoxvirus infections.

Indexed as

Gene DeletionImmunogenicity, VaccineAnimalsCell LineMaleMiceMice, Inbred BALB CSmallpox VaccineVaccines, AttenuatedVaccinia virusViral ProteinsA35R protein, Vaccinia virusSmallpox VaccineVaccines, AttenuatedViral Proteins

Identifiers

PMID27025484
OpenAlexW2316684735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.